Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

Epithelial ovarian cancer (EOC) is hallmarked by a high degree of heterogeneity. To address this heterogeneity, a classification scheme was developed based on gene expression patterns of 1538 tumours. Five, biologically distinct subgroups — Epi‐A, Epi‐B, Mes, Stem‐A and Stem‐B — exhibited significantly distinct clinicopathological characteristics, deregulated pathways and patient prognoses, and were validated using independent datasets. To identify subtype‐specific molecular targets, ovarian cancer cell lines representing these molecular subtypes were screened against a genome‐wide shRNA library. Focusing on the poor‐prognosis Stem‐A subtype, we found that two genes involved in tubulin processing, TUBGCP4 and NAT10, were essential for cell growth, an observation supported by a pathway analysis that also predicted involvement of microtubule‐related processes. Furthermore, we observed that Stem‐A cell lines were indeed more sensitive to inhibitors of tubulin polymerization, vincristine and vinorelbine, than the other subtypes. This subtyping offers new insights into the development of novel diagnostic and personalized treatment for EOC patients.

[1]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[2]  J. Manfredi,et al.  Taxol: an antimitotic agent with a new mechanism of action. , 1984, Pharmacology & therapeutics.

[3]  Edward L. Melnick,et al.  Modeling Survival Data , 2011, International Encyclopedia of Statistical Science.

[4]  G. Castellano,et al.  Tumor and Stem Cell Biology Cancer Research Activation of Phosphatidylcholine Cycle Enzymes in Human Epithelial Ovarian Cancer Cells , 2010 .

[5]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[6]  Terry M. Therneau,et al.  Extending the Cox Model , 1997 .

[7]  Ji-Hyun Kim,et al.  Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap , 2009, Comput. Stat. Data Anal..

[8]  N Mathers,et al.  Empowering research: statistical power in general practice research. , 1997, Family practice.

[9]  N. H. Hanna.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2006 .

[10]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[11]  H. Dressman,et al.  Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Nir Hacohen,et al.  Genome-scale loss-of-function screening with a lentiviral RNAi library , 2006, Nature Methods.

[13]  J. Claverie,et al.  Gene Expression Profile , 2004 .

[14]  S. Mok,et al.  PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas , 2009, Modern Pathology.

[15]  B. Alberts,et al.  Microtubule nucleation by gamma-tubulin-containing rings in the centrosome. , 1995, Nature.

[16]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[17]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[18]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[19]  Pamela N. Munster,et al.  IN HUMAN BREAST CANCER , 2007 .

[20]  G. Acs.  Serous and mucinous borderline (low malignant potential) tumors of the ovary. , 2005, American journal of clinical pathology.

[21]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[22]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[23]  N. Hacohen,et al.  Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.

[24]  R. Gray.  Modeling Survival Data: Extending the Cox Model , 2002 .

[25]  Yudi Pawitan,et al.  Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients , 2006, Breast Cancer Research.

[26]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Patrick O. Brown,et al.  Gene Expression Patterns in Pancreatic Tumors, Cells and Tissues , 2007, PloS one.

[28]  Q. Tan,et al.  Gene Expression Profiles as Prognostic Markers in Women With Ovarian Cancer , 2009, International Journal of Gynecologic Cancer.

[29]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[31]  R. Tothill,et al.  Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors , 2008, Molecular Cancer Research.

[32]  Kathleen R. Cho,et al.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. , 2006, Cancer research.

[33]  Alan R. Dabney.  ClaNC: point-and-click software for classifying microarrays to nearest centroids , 2006, Bioinform..

[34]  J. Mesirov,et al.  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.

[35]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[36]  A. Nobel,et al.  Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data , 2008 .

[37]  B. No̸rgaard-Pedersen,et al.  Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma , 2003, Cancer.

[38]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[39]  Ikuo Konishi,et al.  Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. , 2011, Genome research.

[40]  B. Alberts,et al.  Microtubule nucleation by γ-tubulin-containing rings in the centrosome , 1995, Nature.

[41]  L. Goldstein,et al.  HER-2 testing in breast cancer using parallel tissue-based methods. , 2004, JAMA.

[42]  Q. Tan,et al.  Gene expression in epithelial ovarian cancer: a study of intratumor heterogeneity , 2006, International Journal of Gynecologic Cancer.

[43]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[44]  R. Huang,et al.  Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120‐catenin , 2008, International journal of cancer.

[45]  Carl Virtanen,et al.  Integrated classification of lung tumors and cell lines by expression profiling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Bast,et al.  Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. , 1989, Cancer research.

[47]  C. Gilks,et al.  Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.

[48]  S. Syrjänen,et al.  Detection of human papillomavirus in sinonasal papillomas: Systematic review and meta‐analysis , 2013, The Laryngoscope.

[49]  Jeffrey T. Chang,et al.  Anchorage-independent cell growth signature identifies tumors with metastatic potential , 2009, Oncogene.

[50]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[51]  S L George,et al.  Reducing patient eligibility criteria in cancer clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[53]  Paul Schliekelman,et al.  Statistical Methods in Bioinformatics: An Introduction , 2001 .

[54]  Wen-Lin Kuo,et al.  Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.

[55]  S. Howell.  Advances in the treatment of luminal breast cancer , 2013, Current opinion in obstetrics & gynecology.

[56]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[57]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[58]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[59]  H. Kantarjian,et al.  Imatinib and beyond—exploring the full potential of targeted therapy for CML , 2009, Nature Reviews Clinical Oncology.

[60]  L. Chin,et al.  Making sense of cancer genomic data. , 2011, Genes & development.

[61]  Ron Kohavi,et al.  A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.

[62]  W. Weichert,et al.  A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.

[63]  R. Rosell,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer , 2010, Current opinion in oncology.

[64]  R. Soslow,et al.  Histologic subtypes of ovarian carcinoma: an overview. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[65]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[66]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[67]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[68]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Marketa Zvelebil,et al.  High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing , 2011, Genome Biology.

[70]  H. Johnsen,et al.  Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers , 2011, PloS one.

[71]  B. Chaqour,et al.  Cysteine-rich protein 61 and connective tissue growth factor induce deadhesion and anoikis of retinal pericytes. , 2008, Endocrinology.

[72]  W. Wong,et al.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. , 2009, Cancer cell.

[73]  B. Melichar,et al.  Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  J J Correia,et al.  Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. , 1996, Biochemistry.

[75]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[76]  Robert L Strausberg,et al.  Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. , 2009, Translational oncology.

[77]  R. Roeder,et al.  Purification and characterization of two forms of human transcription factor IIIC. , 1992, The Journal of biological chemistry.

[78]  Michael J. Birrer,et al.  The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer , 2011, The American journal of surgical pathology.

[79]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[80]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[81]  Jotun Hein,et al.  Statistical Methods in Bioinformatics: An Introduction , 2002 .

[82]  Chunyu Liu,et al.  Removing Batch Effects in Analysis of Expression Microarray Data: An Evaluation of Six Batch Adjustment Methods , 2011, PloS one.

[83]  Ying Sun,et al.  NAT10, a nucleolar protein, localizes to the midbody and regulates cytokinesis and acetylation of microtubules. , 2009, Experimental cell research.

[84]  J. Fransson,et al.  Epidermal Growth , 1988, International journal of dermatology.

[85]  J. Ferlay,et al.  Global estimates of cancer prevalence for 27 sites in the adult population in 2008 , 2013, International journal of cancer.

[86]  B. Karlan,et al.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[88]  S. Hirohashi,et al.  Cytoplasmic Beta-Catenin Accumulation as a Predictor of Hematogenous Metastasis in Human Colorectal Cancer , 2000, Oncology.

[89]  John Langford,et al.  Beating the hold-out: bounds for K-fold and progressive cross-validation , 1999, COLT '99.

[90]  Jérôme Couturier,et al.  articleA genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer , 2015 .

[91]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[92]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[93]  Gregory R. Grant,et al.  Statistical Methods in Bioinformatics , 2001 .

[94]  B. Rosen,et al.  Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma , 2008, Clinical Cancer Research.

[95]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[96]  Richard Simon,et al.  An evaluation of resampling methods for assessment of survival risk prediction in high‐dimensional settings , 2011, Statistics in medicine.

[97]  Riccardo Fodde.  The stem of cancer. , 2009, Cancer cell.

[98]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[99]  Lilya V. Matyunina,et al.  Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells , 2009, BMC Medical Genomics.

[100]  B. Monk,et al.  Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. , 2013, Gynecologic oncology.

[101]  S. Gayther,et al.  Ovarian Cancer: A Clinical Challenge That Needs Some Basic Answers , 2009, PLoS medicine.

[102]  P. Ferrara,et al.  HUMAN 76P : A NEW MEMBER OF THE GAMMA -TUBULIN-ASSOCIATED PROTEIN FAMILY , 1999 .

[103]  B. Alberts,et al.  Recruitment of the gamma-tubulin ring complex to Drosophila salt-stripped centrosome scaffolds. , 1998 .

[104]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[105]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.